Eli Lilly’s Stock Price Has Fattened Up Like a Thanksgiving Turkey. Time to (Options) Collar That Green!

Core Insights - Eli Lilly's market capitalization has surpassed $1 trillion, a significant achievement typically associated with technology companies [1] - The company's success is attributed to its advancements in developing drugs for obesity (Zepbound) and diabetes (Mounjaro) [1] - Over the past five years, Eli Lilly's stock has increased by more than 600% [3] Financial Metrics - Eli Lilly's stock is currently priced at 43 times forward earnings, 1.18 times its growth rate, and 22 times sales, indicating it is not cheap based on traditional valuation metrics [4] - The stock has fluctuated between approximately $600 and $900 per share over the past year [7] Market Position and Future Outlook - The company is approaching its 150th anniversary, highlighting its long-standing presence in the pharmaceutical industry [3] - There are questions regarding whether the stock should be viewed as a long-term growth opportunity or merely a momentum trade [6] - Recent technical analysis shows that the stock has broken through a significant price barrier, propelling it into the $1 trillion market cap club [8]